Literature DB >> 21199968

Development of lifetime comorbidity in the World Health Organization world mental health surveys.

Ronald C Kessler1, Johan Ormel, Maria Petukhova, Katie A McLaughlin, Jennifer Greif Green, Leo J Russo, Dan J Stein, Alan M Zaslavsky, Sergio Aguilar-Gaxiola, Jordi Alonso, Laura Andrade, Corina Benjet, Giovanni de Girolamo, Ron de Graaf, Koen Demyttenaere, John Fayyad, Josep Maria Haro, Chi yi Hu, Aimee Karam, Sing Lee, Jean-Pierre Lepine, Herbert Matchsinger, Constanta Mihaescu-Pintia, Jose Posada-Villa, Rajesh Sagar, T Bedirhan Ustün.   

Abstract

CONTEXT: Although numerous studies have examined the role of latent variables in the structure of comorbidity among mental disorders, none has examined their role in the development of comorbidity.
OBJECTIVE: To study the role of latent variables in the development of comorbidity among 18 lifetime DSM-IV disorders in the World Health Organization World Mental Health Surveys.
DESIGN: Nationally or regionally representative community surveys.
SETTING: Fourteen countries. PARTICIPANTS: A total of 21 229 survey respondents. MAIN OUTCOME MEASURES: First onset of 18 lifetime DSM-IV anxiety, mood, behavior, and substance disorders assessed retrospectively in the World Health Organization Composite International Diagnostic Interview.
RESULTS: Separate internalizing (anxiety and mood disorders) and externalizing (behavior and substance disorders) factors were found in exploratory factor analysis of lifetime disorders. Consistently significant positive time-lagged associations were found in survival analyses for virtually all temporally primary lifetime disorders predicting subsequent onset of other disorders. Within-domain (ie, internalizing or externalizing) associations were generally stronger than between-domain associations. Most time-lagged associations were explained by a model that assumed the existence of mediating latent internalizing and externalizing variables. Specific phobia and obsessive-compulsive disorder (internalizing) and hyperactivity and oppositional defiant disorders (externalizing) were the most important predictors. A small number of residual associations remained significant after controlling the latent variables.
CONCLUSIONS: The good fit of the latent variable model suggests that common causal pathways account for most of the comorbidity among the disorders considered herein. These common pathways should be the focus of future research on the development of comorbidity, although several important pairwise associations that cannot be accounted for by latent variables also exist that warrant further focused study.

Entities:  

Mesh:

Year:  2011        PMID: 21199968      PMCID: PMC3057480          DOI: 10.1001/archgenpsychiatry.2010.180

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  52 in total

1.  Conduct and attentional problems in childhood and adolescence and later substance use, abuse and dependence: results of a 25-year longitudinal study.

Authors:  David M Fergusson; L John Horwood; Elizabeth M Ridder
Journal:  Drug Alcohol Depend       Date:  2007-02-09       Impact factor: 4.492

2.  The structure of common mental disorders.

Authors:  R F Krueger
Journal:  Arch Gen Psychiatry       Date:  1999-10

3.  Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys.

Authors:  Josep Maria Haro; Saena Arbabzadeh-Bouchez; Traolach S Brugha; Giovanni de Girolamo; Margaret E Guyer; Robert Jin; Jean Pierre Lepine; Fausto Mazzi; Blanca Reneses; Gemma Vilagut; Nancy A Sampson; Ronald C Kessler
Journal:  Int J Methods Psychiatr Res       Date:  2006       Impact factor: 4.035

4.  Abnormal neural responses to emotional visual stimuli in adolescents with conduct disorder.

Authors:  Philipp Sterzer; Christina Stadler; Annette Krebs; Andreas Kleinschmidt; Fritz Poustka
Journal:  Biol Psychiatry       Date:  2005-01-01       Impact factor: 13.382

5.  The structure and stability of common mental disorders: the NEMESIS study.

Authors:  W A Vollebergh; J Iedema; R V Bijl; R de Graaf; F Smit; J Ormel
Journal:  Arch Gen Psychiatry       Date:  2001-06

Review 6.  Mania and attention-deficit/hyperactivity disorder: common symptomatology, common pathophysiology and common treatment?

Authors:  Ulrich Hegerl; Hubertus Himmerich; Birk Engmann; Tilman Hensch
Journal:  Curr Opin Psychiatry       Date:  2010-01       Impact factor: 4.741

7.  Modeling psychopathology structure: a symptom-level analysis of Axis I and II disorders.

Authors:  K E Markon
Journal:  Psychol Med       Date:  2009-06-11       Impact factor: 7.723

Review 8.  Frontiers between attention deficit hyperactivity disorder and bipolar disorder.

Authors:  Cathryn A Galanter; Ellen Leibenluft
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-04

9.  Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys.

Authors:  Koen Demyttenaere; Ronny Bruffaerts; Jose Posada-Villa; Isabelle Gasquet; Viviane Kovess; Jean Pierre Lepine; Matthias C Angermeyer; Sebastian Bernert; Giovanni de Girolamo; Pierluigi Morosini; Gabriella Polidori; Takehiko Kikkawa; Norito Kawakami; Yutaka Ono; Tadashi Takeshima; Hidenori Uda; Elie G Karam; John A Fayyad; Aimee N Karam; Zeina N Mneimneh; Maria Elena Medina-Mora; Guilherme Borges; Carmen Lara; Ron de Graaf; Johan Ormel; Oye Gureje; Yucun Shen; Yueqin Huang; Mingyuan Zhang; Jordi Alonso; Josep Maria Haro; Gemma Vilagut; Evelyn J Bromet; Semyon Gluzman; Charles Webb; Ronald C Kessler; Kathleen R Merikangas; James C Anthony; Michael R Von Korff; Philip S Wang; Traolach S Brugha; Sergio Aguilar-Gaxiola; Sing Lee; Steven Heeringa; Beth-Ellen Pennell; Alan M Zaslavsky; T Bedirhan Ustun; Somnath Chatterji
Journal:  JAMA       Date:  2004-06-02       Impact factor: 56.272

Review 10.  Emotional disorders: cluster 4 of the proposed meta-structure for DSM-V and ICD-11.

Authors:  D P Goldberg; R F Krueger; G Andrews; M J Hobbs
Journal:  Psychol Med       Date:  2009-10-01       Impact factor: 7.723

View more
  162 in total

Review 1.  Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.

Authors:  Xia Chen; Joop van Gerven; Adam Cohen; Gabriel Jacobs
Journal:  Acta Pharmacol Sin       Date:  2018-12-05       Impact factor: 6.150

2.  Parent psychopathology and offspring mental disorders: results from the WHO World Mental Health Surveys.

Authors:  Katie A McLaughlin; Anne M Gadermann; Irving Hwang; Nancy A Sampson; Ali Al-Hamzawi; Laura Helena Andrade; Matthias C Angermeyer; Corina Benjet; Evelyn J Bromet; Ronny Bruffaerts; José Miguel Caldas-de-Almeida; Giovanni de Girolamo; Ron de Graaf; Silvia Florescu; Oye Gureje; Josep Maria Haro; Hristo Ruskov Hinkov; Itsuko Horiguchi; Chiyi Hu; Aimee Nasser Karam; Viviane Kovess-Masfety; Sing Lee; Samuel D Murphy; S Haque Nizamie; José Posada-Villa; David R Williams; Ronald C Kessler
Journal:  Br J Psychiatry       Date:  2012-03-08       Impact factor: 9.319

3.  Longitudinal twin study of borderline personality disorder traits and substance use in adolescence: developmental change, reciprocal effects, and genetic and environmental influences.

Authors:  Marina A Bornovalova; Brian M Hicks; William G Iacono; Matt McGue
Journal:  Personal Disord       Date:  2012-05-28

4.  Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys.

Authors:  R C Kessler; N A Sampson; P Berglund; M J Gruber; A Al-Hamzawi; L Andrade; B Bunting; K Demyttenaere; S Florescu; G de Girolamo; O Gureje; Y He; C Hu; Y Huang; E Karam; V Kovess-Masfety; S Lee; D Levinson; M E Medina Mora; J Moskalewicz; Y Nakamura; F Navarro-Mateu; M A Oakley Browne; M Piazza; J Posada-Villa; T Slade; M Ten Have; Y Torres; G Vilagut; M Xavier; Z Zarkov; V Shahly; M A Wilcox
Journal:  Epidemiol Psychiatr Sci       Date:  2015-02-27       Impact factor: 6.892

5.  Lifetime co-morbidity of DSM-IV disorders in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A).

Authors:  R C Kessler; S Avenevoli; K A McLaughlin; J Greif Green; M D Lakoma; M Petukhova; D S Pine; N A Sampson; A M Zaslavsky; K Ries Merikangas
Journal:  Psychol Med       Date:  2012-01-25       Impact factor: 7.723

6.  Addiction Models and the Challenge of Having Impact.

Authors:  Meyer D Glantz
Journal:  Alcohol Clin Exp Res       Date:  2019-07-16       Impact factor: 3.455

7.  Exploring Comorbidity Within Mental Disorders Among a Danish National Population.

Authors:  Oleguer Plana-Ripoll; Carsten Bøcker Pedersen; Yan Holtz; Michael E Benros; Søren Dalsgaard; Peter de Jonge; Chun Chieh Fan; Louisa Degenhardt; Andrea Ganna; Aja Neergaard Greve; Jane Gunn; Kim Moesgaard Iburg; Lars Vedel Kessing; Brian K Lee; Carmen C W Lim; Ole Mors; Merete Nordentoft; Anders Prior; Annelieke M Roest; Sukanta Saha; Andrew Schork; James G Scott; Kate M Scott; Terry Stedman; Holger J Sørensen; Thomas Werge; Harvey A Whiteford; Thomas Munk Laursen; Esben Agerbo; Ronald C Kessler; Preben Bo Mortensen; John J McGrath
Journal:  JAMA Psychiatry       Date:  2019-03-01       Impact factor: 21.596

8.  Profiles of childhood trauma and psychopathology: US National Epidemiologic Survey.

Authors:  Emma Curran; Gary Adamson; Michael Rosato; Paul De Cock; Gerard Leavey
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-05-03       Impact factor: 4.328

9.  Should pathological gambling and obesity be considered addictive disorders? A factor analytic study in a nationally representative sample.

Authors:  Carlos Blanco; María García-Anaya; Melanie Wall; José Carlos Pérez de Los Cobos; Ewelina Swierad; Shuai Wang; Nancy M Petry
Journal:  Drug Alcohol Depend       Date:  2015-02-25       Impact factor: 4.492

10.  Aggregation of lifetime Axis I psychiatric disorders through age 30: incidence, predictors, and associated psychosocial outcomes.

Authors:  Richard F Farmer; Derek B Kosty; John R Seeley; Thomas M Olino; Peter M Lewinsohn
Journal:  J Abnorm Psychol       Date:  2013-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.